Shared on15 Aug 25
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.
Shared on24 Apr 25Fair value Increased 54%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.